Effect of 3,4-diaminopyridine at the murine neuromuscular junction

被引:7
|
作者
Ng, Fiona [1 ]
Lee, Diana C. [1 ]
Schrumpf, Leah A. [1 ]
Mazurek, Mary E. [1 ]
Lee, Victoria [1 ]
Gill, Sharleen K. [1 ]
Maselli, Ricardo A. [1 ]
机构
[1] Univ Calif Davis, Sch Med, Dept Neurol, Davis, CA 95616 USA
关键词
3,4-diaminopyridine; Lambert-Eaton myasthenic syndrome; congenital myasthenic syndromes; neuromuscular junction; quantal release; endplate potential; CONGENITAL MYASTHENIC SYNDROME; MUTATIONS; TRANSMISSION; MUSK; 4-AMINOPYRIDINE; PHENOTYPES; ANTIBODY; RELEASE; AGRIN; FROG;
D O I
10.1002/mus.25208
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: We investigated the effects of 3,4-diaminopyridine (3,4-DAP) and its acetylated metabolite, N-(4-amino-pyridin-3-yl) acetamide (3-Ac), at the mammalian neuromuscular junction. Methods: Quantal release of acetylcholine was studied in diaphragm muscles of mice, using in vitro intracellular microelectrode recordings. Results: Under conditions of low probability of release, 3,4-DAP produced a 1,000% increase in quantal release, but 3-Ac had no effect. Under conditions of normal probability of release, the effect of 3,4-DAP was modest and limited by concurrent depletion of synaptic vesicles, especially with high concentrations of 3,4-DAP and high frequencies of nerve stimulation. Conclusions: These findings predict 3,4-DAP is most effective in conditions with low probability of quantal release, such as Lambert-Eaton myasthenic syndrome. A beneficial effect is also expected in disorders of neuromuscular transmission in which the effect of 3,4-DAP on quantal release is not limited by depletion of synaptic vesicles, such as postsynaptic congenital myasthenic syndromes. Muscle Nerve, 2016 Muscle Nerve55: 223-231, 2017
引用
收藏
页码:223 / 231
页数:9
相关论文
共 50 条
  • [21] 3,4-DIAMINOPYRIDINE IN THE TREATMENT OF CONGENITAL (HEREDITARY) MYASTHENIA
    PALACE, J
    WILES, CM
    NEWSOMDAVIS, J
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1991, 54 (12): : 1069 - 1072
  • [22] Pharmacokinetics and tissue distribution of 3,4-diaminopyridine in rats
    Ishida, Natsuko
    Kondo, Yuya
    Chikano, Yuri
    Kobayashi-Nakade, Erina
    Suga, Yukio
    Ishizaki, Junko
    Komai, Kiyonobu
    Matsushita, Ryo
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2019, 40 (08) : 294 - 301
  • [23] COMPARISON OF 4-AMINOPYRIDINE AND 3,4-DIAMINOPYRIDINE IN THE ANTAGONISTIC ACTION TO SKELETAL NEUROMUSCULAR BLOCKADE
    UCHIYAMA, T
    ITO, R
    MOLGO, J
    LEMEIGNAN, M
    LECHAT, P
    JAPANESE JOURNAL OF PHARMACOLOGY, 1984, 36 : P187 - P187
  • [24] 3,4-DIAMINOPYRIDINE IN DEMYELINATING PERIPHERAL NEUROPATHIES - REPLY
    BERGIN, PS
    MILLER, DH
    HIRSCH, NP
    MURRAY, NMF
    ANNALS OF NEUROLOGY, 1994, 36 (03) : 453 - 453
  • [25] INHIBITORY EFFECT OF KANAMYCIN ON EVOKED TRANSMITTER RELEASE - REVERSAL BY 3,4-DIAMINOPYRIDINE
    MOLGO, J
    LEMEIGNAN, M
    UCHIYAMA, T
    LECHAT, P
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1979, 57 (01) : 93 - 97
  • [26] Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus
    Helmchen, C
    Sprenger, A
    Rambold, H
    Sander, T
    Kömpf, D
    Straumann, D
    NEUROLOGY, 2004, 63 (04) : 752 - 752
  • [27] CENTRAL ACTIONS OF SOME DERIVATIVES OF 3,4-DIAMINOPYRIDINE
    AHMAD, A
    PATNAIK, GK
    VOHRA, MM
    INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, 1966, 4 (03) : 154 - &
  • [28] The effect of 3,4-diaminopyridine on the postural imbalance and downbeat nystagmus in patients with ataxia
    Tsunemi, Taiji
    Ishikawa, Kinya
    Mizusawa, Hidehiro
    NEUROLOGY, 2007, 68 (12) : A81 - A81
  • [29] In vitro effect of 3,4-diaminopyridine (3,4-DAP) on neuromuscular transmission in muscle biopsies of patients with different types of congenital myasthenic syndromes (CMS)
    Bowe, CM
    Kong, DZ
    Wollmann, R
    Maselli, RA
    NEUROLOGY, 2000, 54 (07) : A395 - A395
  • [30] THE ACTIONS OF 3,4-DIAMINOPYRIDINE IN BULLFROG SYMPATHETIC-GANGLIA
    APATOFF, B
    RIKER, WK
    BRAIN RESEARCH, 1982, 252 (02) : 277 - 286